Franklin Biotechnology Discovery A
Name
Price
Aum/Mkt Cap
YIELD & DIV
Exp Ratio
Watchlist
Vitals
YTD Return
-12.7%
1 yr return
-17.7%
3 Yr Avg Return
13.0%
5 Yr Avg Return
7.6%
Net Assets
$1.1 B
Holdings in Top 10
43.7%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 0.98%
SALES FEES
Front Load 5.50%
Deferred Load N/A
TRADING FEES
Turnover 47.30%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000
IRA
$250
Fund Classification
Fund Type
Open End Mutual Fund
Investment Style
Health
Name
Price
Aum/Mkt Cap
YIELD & DIV
Exp Ratio
Watchlist
FBDIX - Profile
Distributions
- YTD Total Return -12.7%
- 3 Yr Annualized Total Return 10.9%
- 5 Yr Annualized Total Return 6.4%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.58%
- Dividend Yield 0.9%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameFranklin Biotechnology Discovery Fund
-
Fund Family NameFranklin Templeton Investments
-
Inception DateSep 15, 1997
-
Shares Outstanding7356971
-
Share ClassA
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerEvan McCulloch
Fund Description
Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.
FBDIX - Performance
Return Ranking - Trailing
| Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -12.7% | -30.2% | 25.3% | 61.54% |
| 1 Yr | -17.7% | -33.9% | 33.9% | 95.96% |
| 3 Yr | 13.0%* | 8.8% | 38.7% | 91.22% |
| 5 Yr | 7.6%* | 4.1% | 31.3% | 97.20% |
| 10 Yr | 13.9%* | 8.2% | 22.2% | 86.51% |
* Annualized
Return Ranking - Calendar
| Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2021 | -28.2% | -79.9% | 25.9% | 97.27% |
| 2020 | 13.6% | -13.6% | 178.2% | 54.32% |
| 2019 | 23.3% | 3.8% | 63.8% | 31.72% |
| 2018 | -18.6% | -49.7% | 21.5% | 91.24% |
| 2017 | 16.0% | -59.8% | 54.4% | 59.26% |
Total Return Ranking - Trailing
| Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -12.7% | -30.2% | 25.3% | 74.21% |
| 1 Yr | -22.2% | -33.9% | 31.1% | 98.19% |
| 3 Yr | 10.9%* | -15.9% | 38.7% | 93.30% |
| 5 Yr | 6.4%* | -7.4% | 31.3% | 96.55% |
| 10 Yr | 13.3%* | 8.2% | 22.2% | 86.03% |
* Annualized
Total Return Ranking - Calendar
| Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2021 | -28.2% | -80.0% | 25.9% | 97.27% |
| 2020 | 13.6% | -13.6% | 178.2% | 54.32% |
| 2019 | 23.3% | 3.8% | 63.8% | 31.72% |
| 2018 | -18.6% | -25.3% | 22.2% | 92.70% |
| 2017 | 18.8% | -10.8% | 54.4% | 62.22% |
NAV & Total Return History
FBDIX - Holdings
Concentration Analysis
| FBDIX | Category Low | Category High | FBDIX % Rank | |
|---|---|---|---|---|
| Net Assets | 1.1 B | 2.81 M | 51.6 B | 43.89% |
| Number of Holdings | 105 | 11 | 479 | 30.00% |
| Net Assets in Top 10 | 482 M | 2.18 K | 21.1 B | 32.50% |
| Weighting of Top 10 | 43.65% | 6.8% | 94.7% | 42.50% |
Top 10 Holdings
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
Asset Allocation
| Weighting | Return Low | Return High | FBDIX % Rank | |
|---|---|---|---|---|
| Stocks | 97.88% | 78.80% | 101.13% | 77.08% |
| Other | 1.25% | -23.02% | 4.35% | 7.92% |
| Cash | 0.62% | -0.40% | 12.90% | 34.17% |
| Convertible Bonds | 0.24% | 0.00% | 0.24% | 0.42% |
| Preferred Stocks | 0.00% | 0.00% | 7.04% | 29.58% |
| Bonds | 0.00% | 0.00% | 14.85% | 29.17% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | FBDIX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.69% | 62.01% | 100.00% | 72.50% |
| Financial Services | 1.31% | 0.00% | 1.61% | 5.42% |
| Utilities | 0.00% | 0.00% | 1.33% | 25.42% |
| Technology | 0.00% | 0.00% | 19.99% | 34.17% |
| Real Estate | 0.00% | 0.00% | 5.81% | 29.58% |
| Industrials | 0.00% | 0.00% | 9.31% | 34.58% |
| Energy | 0.00% | 0.00% | 0.68% | 25.42% |
| Communication Services | 0.00% | 0.00% | 7.14% | 27.92% |
| Consumer Defense | 0.00% | 0.00% | 28.15% | 34.17% |
| Consumer Cyclical | 0.00% | 0.00% | 16.11% | 33.75% |
| Basic Materials | 0.00% | 0.00% | 8.80% | 45.83% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | FBDIX % Rank | |
|---|---|---|---|---|
| US | 90.08% | 57.23% | 100.00% | 31.67% |
| Non US | 7.80% | 0.00% | 42.77% | 70.00% |
FBDIX - Expenses
Operational Fees
| FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.98% | 0.08% | 3.13% | 33.90% |
| Management Fee | 0.58% | 0.00% | 1.25% | 34.81% |
| 12b-1 Fee | 0.25% | 0.00% | 1.00% | 33.33% |
| Administrative Fee | 0.15% | 0.03% | 0.25% | 66.67% |
Sales Fees
| FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | 5.50% | 0.00% | 5.75% | 18.07% |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 47.30% | 0.00% | 256.00% | 53.46% |
FBDIX - Distributions
Dividend Yield Analysis
| FBDIX | Category Low | Category High | FBDIX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.94% | 0.00% | 2.44% | 28.33% |
Dividend Distribution Analysis
| FBDIX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Monthly | Semi-Annually |
Net Income Ratio Analysis
| FBDIX | Category Low | Category High | FBDIX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.58% | -2.54% | 1.92% | 77.01% |
Capital Gain Distribution Analysis
| FBDIX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually |
Dividend Payout History
| Date | Amount |
|---|---|
| Dec 19, 2016 | $1.728 |
| Dec 19, 2012 | $0.069 |
| Dec 30, 2011 | $0.515 |
FBDIX - Fund Manager Analysis
Managers
Evan McCulloch
Start Date
Tenure
Tenure Rank
Sep 15, 1997
24.31
24.3%
Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.
Wendy Lam
Start Date
Tenure
Tenure Rank
Sep 01, 2018
3.33
3.3%
Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.
Akiva Felt
Start Date
Tenure
Tenure Rank
Jan 27, 2020
1.93
1.9%
Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.06 | 24.31 | 6.73 | 1.71 |